Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: UMLS:C0684249 (lung carcinoma)
23,830 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A CT scan of a 69-year-old male patient, performed for staging of suspected lung carcinoma, incidentally showed an irregular lesion of 10 cm in the upper abdomen. Further investigation using FDG-PET showed only moderately increased glucose metabolism, whereas Tc-99m MDP SPECT revealed intense osteoblastic activity inside the lesion. A CT-guided biopsy was performed and histologic analysis established the diagnosis of heterotopic mesenteric ossification. This pathology is rare and mostly diagnosed when it is complicated by small bowel obstruction.
...
PMID:Imaging characteristics of heterotopic mesenteric ossification on FDG PET and Tc-99m bone SPECT. 1858 Feb 41

A 74-year-old man was diagnosed with small cell lung carcinoma in the left upper lobe. (18)F-FDG PET/CT showed multifocal strong abnormal uptakes in the axial skeleton and those of the primary lung tumor. CT failed to demonstrate the bony abnormalities. A subsequent (99m)Tc-MDP bone scintigraphy was also almost negative. It is important to note that bone metastasis may be undetectable by both CT and bone scintigraphy even if it is massive.
...
PMID:A Case of Massive Bone Metastases From Lung Cancer Detected Only by 18F-FDG PET/CT. 2601 79

A noncleavable paclitaxel (PTX) and N-acetylmuramyl-l-alanyl-d-isoglutamine (MDP) derivative conjugate, 22 (DY-16-43), and its analogues were prepared and characterized as antagonists of NOD2 signaling. This conjugate enhanced the antitumor and antimetastatic efficacy of PTX in Lewis lung carcinoma (LLC) tumor-bearing mice. This work first describes a molecular strategy that enables the sensitization of a chemotherapeutic response via antagonizing NOD2 inflammatory signaling and suggests NOD2 antagonist as potential adjunct in treating non-small-cell lung cancer (NSCLC).
...
PMID:Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis. 2822 93

Bone is the third metastatic site after liver and lungs. Bone metastases occur in one out of three lung cancers and are usually of osteolytic aspect. Osteolytic bone metastases are responsible of long bone and vertebral fractures leading to restricted mobility, surgery and medullar compression that severely alter quality of life and that have a huge medico-economic impact. In the recent years, Bone Metastatic Multidisciplinary Tumour Board (BM²TB) have been developed to optimize bone metastases management for each patient in harmony with oncology program. In this review, we will go through all the different aspects of bone metastases management including diagnosis and evaluation (CT scan, Tc 99m-MDP bone scan, ¹⁸FDG-PET scan and biopsy for molecular diagnosis), systemic bone treatments (zoledronic acid and denosumab) and local treatments (interventional radiology and radiotherapy). Surgical strategies will be discussed elsewhere. Based on the last 2017-Lung Cancer South East French Guidelines, we present a practical decision tree to help the physicians for decision making in order to reach a personalized locomotor strategy for every patient.
...
PMID:Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management. 2963 Oct 67


<< Previous 1 2

---